drugset / Trial / NCT06272487
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the effect of zilebesiran as add-on therapy in patients with high cardiovascular risk and hypertension not adequately controlled by standard of care antihypertensive medications.
Timeline
- Start
- 2024-02-29
- Primary completion
- 2025-06-19
- Completion
- 2025-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zilebesiran | Unknown | — | Subcutaneous |